Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
复制标题
DOI：
10.1016/j.jaad.2012.06.035
复制
发表时间：
2013-01
影响因子：
13.8
通讯作者：
Gelfand, Joel M.
中科院分区：
文献类型：
--
作者：
Yeung, Howa;Wan, Joy;Van Voorhees, Abby S.;Duffin, Kristina Callis;Krueger, Gerald G.;Kalb, Robert E.;Weisman, Jamie D.;Sperber, Brian R.;Brod, Bruce A.;Schleicher, Stephen M.;Bebo, Bruce F., Jr.;Shin, Daniel B.;Troxel, Andrea B.;Gelfand, Joel M.
关键词：
尽管中重度银屑病普遍不满意且治疗持续性较低，但患者停止治疗的原因仍知之甚少。描述患者报告的在现实临床实践中停止常用中重度银屑病治疗的原因。来自 10 个皮肤科诊所、接受系统治疗的 1,095 名中度至重度斑块状银屑病患者完成了结构化访谈。对所有过去的治疗评估了十一个停止治疗的原因。总共报告了 2,231 次过去的治疗。中位治疗持续时间因治疗而异，范围为 6.0 至 20.5 个月 (p < 0.001)。每个引用的停药原因的频率因治疗而异（所有 p < 0.01）。接受依那西普（OR 5.19；95% CI，3.23-8.33）和阿达木单抗（2.10；1.20-3.67）治疗的患者比接受甲氨蝶呤治疗的患者更有可能出现疗效丧失。与接受甲氨蝶呤治疗的患者相比，接受依那西普 (0.34; 0.23–0.49)、阿达木单抗 (0.48; 0.30–0.75) 和 UVB 光疗 (0.21; 0.14–0.31) 的患者提及副作用的可能性较小，而接受阿维A治疗的患者 (1.56; 1.08–2.25) 则更可能出现副作用所以。接受 UVB 光疗的患者更有可能表示无力承担治疗费用 (7.03; 3.14–15.72)。该研究因其依赖患者回忆而受到限制。在制定公共政策和循证治疗方法以改善成功的长期银屑病控制时，需要考虑不同模式的治疗中断原因。
Despite widespread dissatisfaction and low treatment persistence in moderate-to-severe psoriasis, patients’ reasons behind treatment discontinuation remain poorly understood. To characterize patient-reported reasons for discontinuing commonly used treatments for moderate-to-severe psoriasis in real-world clinical practice. 1,095 patients with moderate-to-severe plaque psoriasis from ten dermatology practices who received systemic treatments completed a structured interview. Eleven reasons for treatment discontinuation were assessed for all past treatments. A total of 2,231 past treatments were reported. Median treatment duration varied by treatment, ranging from 6.0 to 20.5 months (p < 0.001). The frequency of each cited discontinuation reasons differed by treatment (all p < 0.01). Patients who received etanercept (OR 5.19; 95% CI, 3.23–8.33) and adalimumab (2.10; 1.20–3.67) were more likely to cite a loss of efficacy than those who received methotrexate. Patients who received etanercept (0.34; 0.23–0.49), adalimumab (0.48; 0.30–0.75), and UVB phototherapy (0.21; 0.14–0.31) were less likely to cite side effects than those who received methotrexate, while those who received acitretin (1.56; 1.08–2.25) were more likely to do so. Patients who underwent UVB phototherapy were more likely to cite an inability to afford treatment (7.03; 3.14–15.72). The study is limited by its reliance on patient recall. Different patterns of treatment discontinuation reasons are important to consider when developing public policy and evidence-based treatment approaches to improve successful long-term psoriasis control.
登录
查看更多内容
影响因子：
120.7
作者：
Gelfand, Joel M.;Neimann, Andrea L.;Troxel, Andrea B.
通讯作者：
Troxel, Andrea B.
DOI：
10.1111/j.1365-2133.2010.09941.x
发表时间：
2010-09
期刊：
The British journal of dermatology
影响因子：
--
作者：
Abuabara K;Azfar RS;Shin DB;Neimann AL;Troxel AB;Gelfand JM
通讯作者：
Gelfand JM
影响因子：
2.9
作者：
Feldman, SR;Evans, C;Russell, MW
通讯作者：
Russell, MW
影响因子：
11.1
作者：
Ahlehoff, O.;Gislason, G. H.;Hansen, P. R.
通讯作者：
Hansen, P. R.
影响因子：
3.6
作者：
Brunasso, Alexandra Maria Giovanna;Puntoni, Matteo;Massone, Cesare
通讯作者：
Massone, Cesare